Skip to main content
# Title Research Member Research Year
61 Risk-Adapted, Combined-Modality Therapy for Unfavorable Pediatric Hodgkin Lymphom
Prof. Amany Mohamed Ali Ahmed 2018
62 Risk-Adapted, Combined-Modality Therapy for Unfavorable Pediatric Hodgkin Lymphom Dr. Amira Mahmoud Mohammed Osman 2018
63 HCMV Among Pediatrics Acute Lymphoblastic Leukemia Patients in South Egypt Cancer Institute Dr. Khaled Fathy Riad Osman 2018
64 Flowcytometric CD135 Expression
and its Impact on Pediatric Acute
Lymphoblastic Leukemia at South Egypt
Cancer Institute
Prof. Heba Abdel-Razik Sayed Hussein 2018
65 Risk-Adapted, Combined-Modality Therapy for Unfavorable Pediatric Hodgkin Lymphom Prof. Amany Mohamed Ali Ahmed 2018
66 Nutritional Assessment and Intervention Methods in Children at Pediatric Oncology Department Mohammed Zakrya Ahmed Saleh 2018
67 Risk-Adapted, Combined-Modality Therapy for Unfavorable Pediatric Hodgkin Lymphom Dr. Tarek Mohamed Abdel Moneim Mohamed Elsaba Ahmed 2018
68 Flowcytometric CD135 Expression
and its Impact on Pediatric Acute
Lymphoblastic Leukemia at South Egypt
Cancer Institute
Dr. Azaa Shibl Sayed Mahmoud 2018
69 Risk-Adapted, Combined-Modality Therapy for
Unfavorable Pediatric Hodgkin Lymphom
Prof. Amany Mohamed Ali Ahmed 2018
70 Can Pediatric Risk of Mortality Score (PRISM III) Be Used Effectively in Initial Evaluation and Follow-up of Critically Ill Cancer Patients Admitted to Pediatric Oncology Intensive Care Unit (POICU)? A Prospective Study, in a Tertiary Cancer Center in Egy Prof. Heba Abdel-Razik Sayed Hussein 2017